KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Deferred Tax Assets: 2015

Historic Current Deferred Tax Assets for Supernus Pharmaceuticals (SUPN) over the last 1 years, with Dec 2015 value amounting to -$200,000.

  • Supernus Pharmaceuticals' Current Deferred Tax Assets was N/A to -$200,000 in Q4 2015 from the same period last year, while for Dec 2015 it was -$200,000, marking a year-over-year change of. This contributed to the annual value of -$200,000 for FY2015, which is N/A change from last year.
  • As of FY2015, Supernus Pharmaceuticals' Current Deferred Tax Assets stood at -$200,000.
  • Supernus Pharmaceuticals' 5-year Current Deferred Tax Assets high stood at -$200,000 for FY2015, and its period low was -$200,000 during FY2015.
  • Its 1-year average for Current Deferred Tax Assets is -$200,000, with a median of -$200,000 in 2015.